共 50 条
- [41] Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple MyelomaCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11): : 680 - 686Squifflet, PierreMichiels, StefanSiegel, DavidVij, RaviJagannath, SundarSaad, Everardo D.Rajangam, KanyaRo, Sunhee KwonBuyse, Marc
- [42] Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary DiseaseCANCERS, 2020, 12 (04)Zhou, XiangFluechter, PatriciaNickel, KatharinaMeckel, KatharinaMesserschmidt, JaninBoeckle, DavidKnorz, SebastianSteinhardt, Maximilian JohannesKrummenast, FranziskaDanhof, SophiaEinsele, HermannKortuem, K. MartinRasche, Leo
- [43] Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaNEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (02): : 142 - 152Stewart, A. KeithRajkumar, S. VincentDimopoulos, Meletios A.Masszi, TamasSpicka, IvanOriol, AlbertHajek, RomanRosinol, LauraSiegel, David S.Mihaylov, Georgi G.Goranova-Marinova, VesselinaRajnics, PeterSuvorov, AleksandrNiesvizky, RubenJakubowiak, Andrzej J.San-Miguel, Jesus F.Ludwig, HeinzWang, MichaelMaisnar, VladimrMinarik, JiriBensinger, William I.Mateos, Maria-VictoriaBen-Yehuda, DinaKukreti, VishalZojwalla, NaseemTonda, Margaret E.Yang, XinqunXing, BiaoMoreau, PhilippePalumbo, Antonio
- [44] Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple MyelomaANNALS OF PHARMACOTHERAPY, 2013, 47 (01) : 56 - 62Thompson, Jennifer L.
- [45] A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple MyelomaBLOOD, 2014, 124 (21)Keller, JesseFiala, Mark A.Sekhar, JeevanCeriotti, ConnieAllen, MelissaAbboud, Camille N.Stockerl-Goldstein, Keith E.Wildes, Tanya M.Tomasson, Michael H.Vij, Ravi
- [46] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myelomaBlood Cancer Journal, 9Hans C. LeeJatin J. ShahLei FengElisabet E. ManasanchRebecca LuAshley MorpheyBrandon CrumptonKrina K. PatelMichael L. WangRaymond AlexanianSheeba K. ThomasDonna M. WeberRobert Z. Orlowski
- [47] Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomibDRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1525 - 1531Zhao, FangYang, BoWang, JuanZhang, RuiLiu, JingYin, FengleiXu, WeixingHe, Chunyuan
- [48] Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiencyJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Badros, A. Z.Vij, R.Martin, T.Zonder, J. A.Wong, A. F.Woo, T.Boussina, K.Wang, Z.Niesvizky, R.
- [49] Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsEUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (01) : 105 - 114De Novellis, DaniloDerudas, DanieleVincelli, DonatellaFontana, RaffaeleDella Pepa, RobertaPalmieri, SalvatoreAccardi, FabrizioRotondo, FrancescoMorelli, EmanuelaGigliotta, EmiliaRoccotelli, DanielaMarano, LuanaBarone, Maria LuciaCetani, GiusyEsposito, DanielaLazzaro, AntonioDelle Cave, GiuseppeSerio, BiancaMorini, DenisePorrazzo, MarikaUrciuoli, EleonoraMasucci, ChiaraFanelli, FulviaRizzo, MichelaArcamone, ManuelaTrastulli, FabioRocco, StefanoLeone, AldoBianco, RosarioSalvatore, FlaviaIdato, AuroraSicari, MariaTosi, PatriziaRascato, Maria GabriellaDi Perna, MariaFalcone, Antonietta PiaMorello, LuciaCarlisi, MelaniaSvanera, GinoAnnunziata, MarioFrigeri, FerdinandoCalifano, CatelloCarella, Angelo MicheleMarcacci, GianpaoloPane, FabrizioRisitano, Antonio MariaGiudice, ValentinaBotta, CiroSelleri, Carmine
- [50] Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myelomaFUTURE ONCOLOGY, 2022, 18 (24) : 2661 - 2674Kawasaki, AkiraMurakami, HirokazuChou, TakaakiMatsushita, MasaruKizaki, Masahiro